International Journal of Radiation Research
نشریه پرتو پژوه
Int J Radiat Res
Basic Sciences
http://ijrr.com
79
journal79
2322-3243
2345-4229
10.61186/ijrr
en
jalali
1399
10
1
gregorian
2021
1
1
19
1
online
1
fulltext
en
Chemoradiotherapy alone or in combination with Endostar for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis
Medical Physics
Medical Physics
مقاله مروری
Review article
<div style="text-align: justify;">Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined with chemoradiotherapy regimens in the treatment of advanced NSCLC. The retrieval period was from June 2008 to June 2018. A total of 11 RTCs that recruited a total of 735 patients were included. Overall, the results indicated that patients who received Endostar plus chemoradiotherapy showed a significantly increased incidence of objective response rate (ORR) (relative risk [RR] = 1.48; 95% confidence interval [CI] = 1.31–1.67; P < 0.00001) and disease control rate (DCR) (RR = 1.17; 95% CI = 1.09–1.25; P < 0.00001) compared with those who received chemoradiotherapy alone. However, no significant difference was noted between groups for 1-year survival rate (RR = 1.06; 95% CI = 0.91–1.23; P = 0.48). Furthermore, combined Endostar with chemoradiotherapy did not yield a high incidence of stable and elevated Karnofsky performance score (RR = 1.06; 95% CI = 0.91–1.23; P = 0.48). Moreover, no significant difference was noted in the incidence of total toxicity between the two groups. The findings of our study indicated that treatment with Endostar plus chemoradiotherapy yielded a high incidence of ORR or DCR, but did not trigger excess adverse events in patients with NSCLC.</div>
Endostar, Lung cancer, Chemoradiotherapy, Meta-analysis, Efficacy, Safety.
1
12
http://ijrr.com/browse.php?a_code=A-10-2055-80&slc_lang=en&sid=1
Z.C.
Tao
7900319475328460019913
7900319475328460019913
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
J.
Qiu
7900319475328460019914
7900319475328460019914
No
Department of Imaging, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
Y.Y.
Zhang
7900319475328460019915
7900319475328460019915
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
L.
Qian
money2004@sina.com
7900319475328460019916
7900319475328460019916
Yes
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
J.
Gao
gj11667@126.com
7900319475328460019917
7900319475328460019917
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
Y.
Zhou
7900319475328460019918
7900319475328460019918
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
L.
Yang
7900319475328460019919
7900319475328460019919
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
J.
He
7900319475328460019920
7900319475328460019920
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
J.
Yang
7900319475328460019921
7900319475328460019921
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
R.
Wang
7900319475328460019922
7900319475328460019922
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
Y.
Huang
7900319475328460019923
7900319475328460019923
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
L.
Zhou
7900319475328460019924
7900319475328460019924
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
B.
Sun
7900319475328460019925
7900319475328460019925
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China
Y.Y.
Cui
7900319475328460019926
7900319475328460019926
No
Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China